BC Innovations | Nov 6, 2014
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Liposome-supported peritoneal dialysis for detoxification Rat studies suggest liposome-supported dialysis could be useful for extracting excess metabolites and drugs from the peritoneal cavity. In rats,...
BioCentury | Jul 1, 2013
Finance

2Q Stock Wrap-Up: If it ain't broke

Despite one segment that finished the second quarter in the red, all market cap groups are still up for the year. In 2Q13, the sector was led by large caps, which closed up 4%, marking...
BC Week In Review | May 25, 2009
Clinical News

Extraneal regulatory update

FDA approved a boxed warning to the label of Extraneal peritoneal dialysis solution to warn of dangerous drug-device interaction. The boxed warning states that blood glucose measurement in patients receiving Extraneal must be done with...
BioCentury | Sep 8, 2008
Regulation

Refinement wanted

Refinement wanted As mandated by the FDA Amendments Act of 2007, FDA last week released its first quarterly report on potential signals of risk for marketed drugs. Under FDAAA, the agency must report new safety...
BC Week In Review | Aug 7, 2006
Clinical News

Adept icodextrin regulatory update

FDA approved a PMA for Adept 4% icodextrin as an adjunct to reduce post-operative adhesions in patients undergoing gynecological laparoscopic adhesiolysis. Baxter BioSurgery, which has worldwide marketing rights to Adept, will launch the product in...
BC Week In Review | Jun 5, 2006
Clinical News

Adept icodextrin regulatory update

IOV received an approvable letter for a PMA for Adept to reduce post-operative adhesions in patients undergoing gynecological laparoscopic adhesiolysis. FDA requested an amended label copy for adverse event data and warnings and proposals for...
BC Week In Review | Jun 27, 2005
Company News

ML Lab, Shire Pharmaceuticals Group plc sales and marketing update

SHP will return European marketing rights to Adept icodextrin to MLB effective Dec. 30. The drug is approved to reduce post-operative abdominal adhesions in the EU, where it has annual sales of $5 million. SHP...
BioCentury | Jun 27, 2005
Finance

Ebb & Flow

Two industry veterans last week unveiled plans for a $1 billion structured product development fund that seeks to capitalize on the industry's current fascination with late-stage clinical products. A major part of its strategy will...
BC Extra | Jun 22, 2005
Company News

Shire returns Adept rights

Shire (LSE:SHP; SHPGY) will return European marketing rights to Adept icodextrin to ML Labs (LSE:MLB) effective Dec. 30. The drug is approved in the EU to reduce post-operative abdominal adhesions; it has annual sales of...
BC Week In Review | May 16, 2005
Clinical News

Adept icodextrin regulatory update

FDA accepted for filing a PMA for Adept icodextrin solution to reduce post-operative abdominal adhesions. Adept already is marketed in Europe for this indication. ML Laboratories plc (LSE:MLB), Warrington, U.K.   Shire Pharmaceuticals Group plc...
Items per page:
1 - 10 of 25